Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy

Blood (2023) 141 (7): 756–765.

https://doi.org/10.1182/blood.2022017848

Published: 2023

Includes: Supplemental data

Journal Articles

Extramedullary Relapse Post CAR-T

Shambavi Richard, Guido Lancman, Adriana Rossi, Ajai Chari, Samir Parekh, Larysa Sanchez, Cesar Rodriguez, Hearn J. Cho, Joshua Richter, Santiago Thibaud, Kiah Purcell, Elizabeth Aronson, Daniel Verina, Juliet Escalon, Karen Louw, Sundar Jagannath

Blood (2022) 140 (Supplement 1): 4301–4302.

https://doi.org/10.1182/blood-2022-170119

Published: 2022

Journal Articles

Myeloma Developing Regimens Using Genomics (MyDRUG): Longitudinal Single-Cell Transcriptional Landscape of the Myeloma and Immune Microenvironment in Relapsed/Refractory Multiple Myeloma Patients Treated with MEK-Inhibitor, Cobimetinib

Reyka G. Jayasinghe, George Mulligan, April Cook, Mark Hamilton, Sacha Gnjatic, Seunghee Kim-Schulze, Hearn J. Cho, Shaji K Kumar

Blood (2022) 140 (Supplement 1): 7090–7091.

https://doi.org/10.1182/blood-2022-167462

Published: 2022

Journal Articles

Infections and Severe Hypogammaglobulinemia in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

Guido Lancman, Kian Parsa, Cesar Rodriguez, Joshua Richter, Hearn J. Cho, Samir Parekh, Shambavi Richard, Adriana Rossi, Larysa Sanchez, Santiago Thibaud, Sundar Jagannath, Ajai Chari

Blood (2022) 140 (Supplement 1): 10073–10074.

https://doi.org/10.1182/blood-2022-163733

Published: 2022

Journal Articles

Novel Transcriptomics Based Stratification Approach Using the Commpass Dataset Reveals Mechanistic Insights into Current and Upcoming MM Therapies

Habib Hamidi, Teiko Sumiyoshi, Cedric E. Dos Santos, Samuel Tracy, Hearn J. Cho, Stephanie Hilz, Vivek S. Chopra

Blood (2022) 140 (Supplement 1): 7208–7210.

https://doi.org/10.1182/blood-2022-163868

Published: 2022

Journal Articles

Timing and Nature of Infections in Multiple Myeloma Patients Treated with Anti-BCMA CAR-T Cells

Guido Lancman, Margaret Shyu, Megan Metzger, Kian Parsa, Hearn J. Cho, Samir Parekh, Joshua Richter, Cesar Rodriguez, Adriana Rossi, Larysa Sanchez, Santiago Thibaud, Sundar Jagannath, Ajai Chari, Shambavi Richard

Blood (2022) 140 (Supplement 1): 7198–7199.

https://doi.org/10.1182/blood-2022-163757

Published: 2022

Journal Articles

Salvage with Sequential T Cell Redirection for Myeloma Patients Who Have Previously Progressed on T Cell Directed Therapy Is Associated with Significant Cellular Activation of the Immune Microenvironment

Adolfo Aleman, Ariel Kogan Zajdman, Yogita Ghodke-Puranik, Bhaskar Upadhyaya, Tarek H. Mouhieddine, Oliver Van Oekelen, Larysa Sanchez, Shambavi Richard, Adriana Rossi, Joshua Richter, Hearn J. Cho, Cesar Rodriguez, Ajai Chari, Sundar Jagannath, Samir Parekh

Blood (2022) 140 (Supplement 1): 4193–4195.

https://doi.org/10.1182/blood-2022-169538

Published: 2022

Journal Articles

The Mydrug Platform Trial: Efficacy and Safety of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone in Patients with Functionally High-Risk Multiple Myeloma

Shaji K Kumar, Craig C Hofmeister, Noa Biran, Gurbakhash Kaur, Jing Christine Ye, Jeffrey A. Zonder, Umar Syed, Jennifer Yesil, Karen Woolley, George Mulligan, Hearn J. Cho

Blood (2022) 140 (Supplement 1): 4434–4435.

https://doi.org/10.1182/blood-2022-163737

Published: 2022

Journal Articles

Gain of chr1q Portends Poor Outcomes in Multiple Myeloma Patients Treated with Venetoclax

Alessandro Lagana, Santiago Thibaud, David T. Melnekoff, Paula Restrepo, Violetta Leshchenko, Jonathan McCafferty, Scott Newman, Abbi Kern, David Corrigan, Feras Hantash, Adriana Rossi, Cesar Rodriguez, Larysa Sanchez, Shambavi Richard, Ajai Chari, Hearn J. Cho, Sundar Jagannath, Joshua Richter, Samir Parekh

Blood (2022) 140 (Supplement 1): 4388–4390.

https://doi.org/10.1182/blood-2022-166572

Published: 2022

Journal Articles

Immune Recovery Post BCMA CAR-T: Implications for Infection Prophylaxis and Vaccinations

Shambavi Richard, Guido Lancman, Santiago Thibaud, Ajai Chari, Samir Parekh, Adriana Rossi, Hearn J. Cho, Larysa Sanchez, Joshua Richter, Cesar Rodriguez, Elizabeth Aronson, Karen Louw, Kiah Purcell, Daniel Verina, Juliet Escalon, Sundar Jagannath

Blood (2022) 140 (Supplement 1): 7444–7446.

https://doi.org/10.1182/blood-2022-170404

Published: 2022

Journal Articles

Comprehensive Characterization of Prolonged Unexplained Cytopenias in Relapsed/Refractory Multiple Myeloma Patients Following BCMA-Directed CAR-T Cell Therapy

Blood (2022) 140 (Supplement 1): 614–616.

https://doi.org/10.1182/blood-2022-165646

Published: 2022

Journal Articles

Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma

Rachid C. Baz, Thomas G. Martin, III, Hui-Yi Lin, Xiuhua Zhao, Kenneth H. Shain, Hearn J. Cho, Jeffrey L. Wolf, Anuj Mahindra, Ajai Chari, Daniel M. Sullivan, Lisa A. Nardelli, Kenneth Lau, Melissa Alsina, Sundar Jagannath

Blood (2016) 127 (21): 2561–2568.

https://doi.org/10.1182/blood-2015-11-682518

Published: 2016

Includes: Supplemental data

Journal Articles

Pomalidomide, Cyclophosphamide, and Dexamethasone Is Superior to Pomalidomide and Dexamethasone in Relapsed and Refractory Myeloma: Results of a Multicenter Randomized Phase II Study

Rachid Baz, MD, Thomas G. Martin, MD, Melissa Alsina, MD, Kenneth H. Shain, MD PhD, Hearn J. Cho, MD PhD, Jeffrey L Wolf, MD, Anuj Mahindra, MD, Ajai Chari, MD, Daniel M Sullivan, MD, Lisa A Nardelli, BS, CCRP, Kenneth Lau, BA, Xiuhua Zhao, Hui-Yi Lin, PhD, Sundar Jagannath, MD

Blood (2014) 124 (21): 303.

https://doi.org/10.1182/blood.V124.21.303.303

Published: 2014

Journal Articles

A Phase II, Single-Center, Open-Label Study of Oral Panobinostat in Combination with Lenalidomide and Weekly Dexamethasone in Patients with Multiple Myeloma

Ajai Chari, MD, Hearn J. Cho, MD PhD, Samir Parekh, MD, Amishi Dhadiwal, Katarzyna Garcia, MS, Natalie Belostotsky, Donna Catamero, NP, Arlynn Brion, Lauren Cardone, Juliet Escalaon, Daniel Verina, Moon-hee Yum, Lisa La, MS, Jude Gullie, BA, Elaine Chan, BS, Sundar Jagannath, MD

Blood (2014) 124 (21): 3486.

https://doi.org/10.1182/blood.V124.21.3486.3486

Published: 2014

Journal Articles

Recombinant (rec) MAGE-A3 Protein Immunotherapy and Peripheral Blood Lymphocyte (PBL) Reconstitution Induce Strong Antigen-Specific Humoral and Cellular Immune Responses in Patients Undergoing Autologous Stem Cell Transplantation (ASCT) for Consolidation of Multiple Myeloma (MM)

Adam D. Cohen, MD, Nikoletta Lendvai, MDPhD, Sacha Gnjatic, PhD, Achim A Jungbluth, MD, Stephane Bertolini, Linda Pan, Pharm.D., Ralph Venhaus, Ioanna Tsakos, Katarzyna Garcia, MS, Linda Thibodeau, RN, Katherine Alpaugh, PhD, Nailah Cummings, Rafik Fellague-Chebra, MD, Olivier Gruselle, Hearn J. Cho, MD PhD

Blood (2014) 124 (21): 1184.

https://doi.org/10.1182/blood.V124.21.1184.1184

Published: 2014

Journal Articles

Pre-Clinical Analysis Of The Novel Antifolate Pralatrexate In Multiple Myeloma Reveals Functional Biomarkers Correlated With Response

Michael Mangone, PhD, Anna H Mei, BA, Luigi Scotto, PhD, Michele Visentin, PhD, Enrica Marchi, MD, PhD, I. David Goldman, MD, Constantine S. Mitsiades, MD, PhD, Owen A. O'Connor, MD, PhD, Hearn J. Cho, MD, PhD

Blood (2013) 122 (21): 4430.

https://doi.org/10.1182/blood.V122.21.4430.4430

Published: 2013

Journal Articles

Pomalidomide (Pom) Dexamethasone (D) With Or Without Oral Weekly Cyclophosphamide (Cy) For Lenalidomide Refractory Multiple Myeloma (LRMM): A Multicenter Randomized Phase II Trial

Rachid Baz, MD, Thomas G Martin, III, MD, Melissa Alsina, MD, Kenneth H. Shain, MD, PhD, Hearn J. Cho, MD, PhD, Jeffrey L Wolf, MD, Anuj Mahindra, M.D., Ajai Chari, MD, Daniel Sullivan, M.D., Lisa A Nardelli, BS, CCRP, Kenneth Lau, BA, Hui-Yi Lin, PhD, Sundar Jagannath, MD

Blood (2013) 122 (21): 3200.

https://doi.org/10.1182/blood.V122.21.3200.3200

Published: 2013

Journal Articles

A Phase II, Single-Center, Open-Label Study Of Oral Panobinostat In Combination With Lenalidomide and Weekly Dexamethasone In Patients With Multiple Myeloma

Noa Biran, MD, Samira Shahnaz, MD, Sundar Jagannath, MD, Hearn J. Cho, MD, PhD, Keren Osman, MD, Samir Parekh, MD, Danielle Choi, RN, Katarzyna Garcia, MS, Donna Catamero, NP, Lisa La, MS, Jude Gullie, BA, Elaine Chan, BS, Ajai Chari, MD

Blood (2013) 122 (21): 5392.

https://doi.org/10.1182/blood.V122.21.5392.5392

Published: 2013

Journal Articles

MAGE-A3 Recombinant Protein (recMAGE-A3) Immunotherapy and Autologous Peripheral Blood Lymphocyte (PBL) Infusion Is Safe and Induces Robust Humoral Immune Responses In Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplantation (autoSCT)

Adam D Cohen, MD, Nikoletta Lendvai, MD PhD, Sacha Gnjatic, Ph.D., Achim A Jungbluth, MD, Stephane Bertolini, Linda Pan, Pharm.D., Ralph Venhaus, Ioanna Tsakos, Katarzyna Garcia, MS, Linda Thibodeau, RN, Katherine Alpaugh, PhD, Nailah Cummings, Rafik Fellague-Chebra, MD, Olivier Gruselle, Hearn J. Cho, MD, PhD

Blood (2013) 122 (21): 154.

https://doi.org/10.1182/blood.V122.21.154.154

Published: 2013

Journal Articles

Pralatrexate Has Potent Activity Against Multiple Myeloma In Vitro and In Vivo , and Activity Correlates with Tumor RFC-1 and DHFR Expression

Michael Mangone, AB, Luigi Scotto, Ph.D., Enrica Marchi, MD, Ph.D., Owen A. O'Connor, MD, PhD, Hearn J. Cho, MD, PhD

Blood (2011) 118 (21): 1831.

https://doi.org/10.1182/blood.V118.21.1831.1831

Published: 2011

NARROW

Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy

Extramedullary Relapse Post CAR-T

Myeloma Developing Regimens Using Genomics (MyDRUG): Longitudinal Single-Cell Transcriptional Landscape of the Myeloma and Immune Microenvironment in Relapsed/Refractory Multiple Myeloma Patients Treated with MEK-Inhibitor, Cobimetinib

Infections and Severe Hypogammaglobulinemia in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

Novel Transcriptomics Based Stratification Approach Using the Commpass Dataset Reveals Mechanistic Insights into Current and Upcoming MM Therapies

Timing and Nature of Infections in Multiple Myeloma Patients Treated with Anti-BCMA CAR-T Cells

Salvage with Sequential T Cell Redirection for Myeloma Patients Who Have Previously Progressed on T Cell Directed Therapy Is Associated with Significant Cellular Activation of the Immune Microenvironment

The Mydrug Platform Trial: Efficacy and Safety of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone in Patients with Functionally High-Risk Multiple Myeloma

Gain of chr1q Portends Poor Outcomes in Multiple Myeloma Patients Treated with Venetoclax

Immune Recovery Post BCMA CAR-T: Implications for Infection Prophylaxis and Vaccinations

Comprehensive Characterization of Prolonged Unexplained Cytopenias in Relapsed/Refractory Multiple Myeloma Patients Following BCMA-Directed CAR-T Cell Therapy

Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma

Pomalidomide, Cyclophosphamide, and Dexamethasone Is Superior to Pomalidomide and Dexamethasone in Relapsed and Refractory Myeloma: Results of a Multicenter Randomized Phase II Study

A Phase II, Single-Center, Open-Label Study of Oral Panobinostat in Combination with Lenalidomide and Weekly Dexamethasone in Patients with Multiple Myeloma

Recombinant (rec) MAGE-A3 Protein Immunotherapy and Peripheral Blood Lymphocyte (PBL) Reconstitution Induce Strong Antigen-Specific Humoral and Cellular Immune Responses in Patients Undergoing Autologous Stem Cell Transplantation (ASCT) for Consolidation of Multiple Myeloma (MM)

Pre-Clinical Analysis Of The Novel Antifolate Pralatrexate In Multiple Myeloma Reveals Functional Biomarkers Correlated With Response

Pomalidomide (Pom) Dexamethasone (D) With Or Without Oral Weekly Cyclophosphamide (Cy) For Lenalidomide Refractory Multiple Myeloma (LRMM): A Multicenter Randomized Phase II Trial

A Phase II, Single-Center, Open-Label Study Of Oral Panobinostat In Combination With Lenalidomide and Weekly Dexamethasone In Patients With Multiple Myeloma

MAGE-A3 Recombinant Protein (recMAGE-A3) Immunotherapy and Autologous Peripheral Blood Lymphocyte (PBL) Infusion Is Safe and Induces Robust Humoral Immune Responses In Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplantation (autoSCT)

Pralatrexate Has Potent Activity Against Multiple Myeloma In Vitro and In Vivo , and Activity Correlates with Tumor RFC-1 and DHFR Expression

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only